

A2  
been reported [Matsumoto et al., J. Exp. Med. 181, 115-125 (1995)]. Further, the primary structure has been reported [Nature Med., 3: 1266-1270 (1997)] (Japanese Patent Unexamined Publication No. Hei 9-157295).

A2  
Kindly insert the enclosed sequence listing into the application between the last page of the specification (page 7) and the first page of the claims (page 8).

**IN THE CLAIMS**

Kindly amend the noted claims to read as follows:

- A4
1. Cytokine inducers comprising a protein *Mycoplasma fermentans* 161 Ag (M161Ag) or gene recombination products thereof.
  2. The cytokine inducers according to claim 1 wherein the induced cytokines are interleukin-1-beta (IL-1- $\beta$ ), tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12) and/or interferon-gamma (IFN- $\gamma$ ).
- 
- A5
9. A method of induction of cytokines comprising administration of protein M161Ag or gene recombination products thereof.
  10. A method of treating immunological diseases comprising administration of protein M161Ag or gene recombination products thereof.

**REMARKS**

Claims 1-2 and 9-10 have been amended. The specification also has been amended to correct various informalities and to include sequence listings for two sequences. No new matter is presented by virtue of these amendments. For example, support for these amendments may be found throughout the specification and in the original claims of the application.